PubHawk
January 2012 PMID 22077192

Rivaroxaban in patients with a recent acute coronary syndrome.

Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun

Download social card

Mentions

111
Peak: 6 in May 2020
across 5 sources since Jun 2019

Extended reach

145,227
potential audience

Total likes

92

Video views

2,085

Mentions per month

Jun 2019 – Mar 2024

Where it's discussed

  • News63 articles
  • X / Twitter23 posts
  • Facebook11 posts
  • Blogs11 articles
  • YouTube3 videos

AI synopsis

What people are saying

The overall tone reflects strong agreement about the benefits of rivaroxaban in acute coronary syndrome, with discussions citing specific trials like ATLAS TIMI-51 that showed mortality benefits and reductions in embolic strokes. The language emphasizes the importance of these findings, with phrases like 'massive reduction' and questions about future trials, indicating deep engagement and recognition of potential impacts on clinical practice.

AgreementModerate agreement

Most discussions recognize the positive findings of the trials, especially the mortality reduction with rivaroxaban, indicating broad agreement on its benefits.

InterestHigh interest

The discussions demonstrate high curiosity, referencing multiple studies, doses, and potential future trials, showing strong engagement with the topic.

EngagementHigh engagement

Participants delve into detailed analysis of trial results, safety concerns, and clinical implications, reflecting deep involvement.

ImpactHigh impact

The conversations highlight significant potential shifts in treatment strategies and the importance of further research, emphasizing high clinical impact.

Abstract in brief

  • Rivaroxaban, a factor Xa inhibitor, was tested in a trial with patients who recently experienced an acute coronary syndrome (ACS), and it was shown to lower the risk of death, heart attack, or stroke compared to a placebo.
  • The study found that the higher dose of 25 mg twice daily not only reduced these cardiovascular events but also decreased death rates from heart-related causes, although it increased the risk of major bleeding and intracranial hemorrhage.
  • While the 25 mg dose offered survival benefits, both doses increased bleeding risks, but the lower dose had fewer fatal bleeding events, highlighting a balance between benefits and risks in using rivaroxaban after ACS.
Read the full abstract

Top posts

Most liked on X and Bluesky
SABOURETCardiologist
@SABOURETCardio · X

Rivaroxaban in Patients with a Recent ACS| NEJM https://t.co/LcNoQlj6b7 #cardiotwitter Open for discussion

May 22, 2020 · 9 likes · 2 shares · 31,171 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U and COMPASS studies https://t.co/iPx4M1F9HE both showed impressive reductions in embolic stroke & death. I'd suggest we need a trial in LV thrombus of VKA versus triple therapy of DAPT+RIVA 2.5mg bid

Jul 23, 2019 · 7 likes · 3 shares · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio @rafavidalperez @DrRajivsankar @rbcasado @DrRaniKhatib @RandyKoh24 @SeanM_Wu @Derek_Leong_RPh @VictorDayan1 @OlivierHoffman @HeartOTXHeartMD @SuzanneArtMusic @ihtanboga @drwilsonjr optimal DAPT or optimal anticoagulation buddy ? everybody forgets that ATLAS TIMI-51 lowered total mortality by 1/3 in ACS in the group given aspirin & P2Y12 & baby dose rivaroxaban versus DAPT https://t.co/DYGAOgNv0U https://t.co/1WrRExlkQ1 @CMichaelGibson @DLBHATTMD

Apr 10, 2020 · 6 likes · 1 share · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@Coronary4front @mirvatalasnag @GreggWStone @mmamas1973 @djc795 @HollandTamis @SripalBangalore @NielsRHolm @gbiondizoccai @DocSavageTJU @DFCapodanno @sbrugaletta @FaisalBakaeen @JoeSabik @RuelMarc1 @pomyers @VictorDayan1 @GianTorre610 @RMSSAA these patients were not randomized in our Compass-PCI study but this is what we do at Birmingham City Hospital https://t.co/G7IHwr7wiv [this built on the TIMI-51 study] https://t.co/DYGAOgNv0U

Mar 3, 2024 · 6 likes · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio @DocSavageTJU @mmamas1973 @DrMarthaGulati @GreggWStone @Drroxmehran @rwyeh @SVRaoMD @DLBHATTMD @mirvatalasnag @sbrugaletta @HeartOTXHeartMD @willsuh76 @djc795 @sloaneguy @fischman_david @CMichaelGibson @DrSoniaAnand1 not in Atlas TIMI 51 "median time from index event to randomization was 4.7 days" https://t.co/DYGAOgNv0U this @CMichaelGibson paper argues for riva + SAPT https://t.co/oZ4Rwin5HD be interested in @DLBHATTMD view

Oct 4, 2019 · 6 likes · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@mmamas1973 @pabeda1 @djc795 @SVRaoMD @EmileMehanna @cardioPCImom @Pooh_Velagapudi @nolanjimradial @Heartdoc530 @DrMauricioCohen @hect2701 @hectortamezmd @vass_vassiliou @evandrofilhobr @rwyeh @FahmiJFarah @Ravi_Hira_MD @aymanka @DrFerNunez @RodrigoBagur I agree and we often marinate these patients / treat medically in the first instance. Rivaroxaban already has a NICE recommendation https://t.co/1WrRExlkQ1 based on the Atlas TIMI 51 Trial https://t.co/DYGAOgNv0U Be interesting to do a trial !!

Jun 2, 2019 · 5 likes · 3,933 followers View post →

All mentions

Prof Derek Connolly
@DrDerekConnolly · X

@Coronary4front @mirvatalasnag @GreggWStone @mmamas1973 @djc795 @HollandTamis @SripalBangalore @NielsRHolm @gbiondizoccai @DocSavageTJU @DFCapodanno @sbrugaletta @FaisalBakaeen @JoeSabik @RuelMarc1 @pomyers @VictorDayan1 @GianTorre610 @RMSSAA these patients were not randomized in our Compass-PCI study but this is what we do at Birmingham City Hospital https://t.co/G7IHwr7wiv [this built on the TIMI-51 study] https://t.co/DYGAOgNv0U

Mar 3, 2024 · 6 likes · 3,933 followers View post →
Matias Rodriguez G
@matiasrg · X

Apr 10, 2022 · 5 likes · 1,394 followers View post →
Matías Montero
@Matias_MM_1996 · X

Protocolo Atlas: Rivaroxabán 2,5 mg cada 12h en pacientes con SCA reciente. Resultados: menos muertes cardiovasculares y generales. Dosis de 5 mg cada 12h no mostraron beneficio y aumentaron las complicaciones hemorrágicas. DOI: 10.1056/NEJMoa1112277

Mar 1, 2022 · 3 likes · 103 followers View post →
Dr. Shashank Joshi
@AskDrShashank · X

RT @DrDerekConnolly: @SABOURETCardio interestingly, in ATLAS ACS2 TIMI-51 study, in which 1/3 were >65& 9% >75, adding Rivaroxaban 2.5 mg…

May 30, 2021 · 1 share · 32,516 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio interestingly, in ATLAS ACS2 TIMI-51 study, in which 1/3 were >65& 9% >75, adding Rivaroxaban 2.5 mg bd to Aspirin & Clopidogrel resulted in a 32% reduction in total mortality over aspirin and clopidogrel alone time to do a new trial https://t.co/TSpsp5Dnpa @vlgmrc

May 30, 2021 · 4 likes · 1 share · 3,933 followers View post →
Almansour
@malmansour81 · X

RT @DrDerekConnolly: @DFCapodanno great review Davide, and I absolutely agree remember that in ATLAS-TIMI 51 Riva 2.5 mg bd [i.e. the sam…

Sep 24, 2020 · 1 share · 213 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@DFCapodanno great review Davide, and I absolutely agree remember that in ATLAS-TIMI 51 Riva 2.5 mg bd [i.e. the same dose we used in PCI Compass] had a massive 32 % reduction in total mortality largely driven by reduction in stroke too. https://t.co/TspxyleelL

Sep 23, 2020 · 3 likes · 1 share · 3,933 followers View post →
Juan Senior
@jsenior64 · X

El Rivaroxaban demostró reducción el desenlace primario en el ATLAS ACS-2 TIMI 51, sin embargo con costo en sangrado, sangrado mayor y sangrado intracraneal, razón por la cual no fue muy popular la estrategia. https://t.co/dnK4sLkME9

Sep 13, 2020 · 1 like · 11,074 followers View post →
Giuseppe Biondi-Zoccai
@gbiondizoccai · X

RT @djc795: @purviparwani @SABOURETCardio @GuptaRMD @mmamas1973 @ShariqShamimMD @AJTafur @fspmd @adityadoc1 @mirvatalasnag @sbrugaletta @An…

Sep 9, 2020 · 1 share · 12,163 followers View post →
Juan Manuel Hernandez
@JuanmaHernande · X

RT @SABOURETCardio: Rivaroxaban in Patients with a Recent ACS| NEJM https://t.co/LcNoQlj6b7 #cardiotwitter Open for discussion

May 22, 2020 · 2 shares · 284 followers View post →
SABOURETCardiologist
@SABOURETCardio · X

Rivaroxaban in Patients with a Recent ACS| NEJM https://t.co/LcNoQlj6b7 #cardiotwitter Open for discussion

May 22, 2020 · 9 likes · 2 shares · 31,171 followers View post →
degustador de microplásticos
@joaumdoistres · X

@GolfinEntDoc @LiangRhea @fessdoc https://t.co/4WISJ7pE40 here, this is the trial

May 20, 2020 · 1 like · 3,136 followers View post →
degustador de microplásticos
@joaumdoistres · X

@RelativeBrain @fvguima Não se usa rivaroxabana 2,5mg pra anticoagular FA. Tem um trabalho do NEJM em que essa dose reduziu eventos isquêmicos mas aumentou sangramentos (chocante!). https://t.co/4WISJ7pE40

May 20, 2020 · 3,136 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@ncurzen there was no difference in total mortality of ASA v P2Y12i in Compass we showed a total mortality benefit [HR=0.82] of ASA+baby dose RIVA over ASA but the authors gloss over that I'd say death is more important than bleeding https://t.co/iPx4M1F9HE [https://t.co/DYGAOgNv0U] https://t.co/75U3FsShHh

May 20, 2020 · 1 like · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio @adelhosieny @EkateriniL @DocSavageTJU @DavidWienerMD @fischman_david @saia_francesco @Costa_F_8 @ncurzen @doctstefania @HeartOTXHeartMD @iamritu @El_Cavarretta @gbiondizoccai why do people ignore ATLAS TIMI-51 1/3 CV mortality benefit Pierre? I know it's in ACS but it's massive and not seen in all the recent trials https://t.co/DYGAOgNv0U and don't we need a GEMINI-ACS 2 [low NOAC +P2Y12i]? https://t.co/SCdq7cbdGE

May 19, 2020 · 2 likes · 3,933 followers View post →
Raul Villar
@DrRaulvillar · X

RT @DrDerekConnolly: @SABOURETCardio @rafavidalperez @DrRajivsankar @rbcasado @DrRaniKhatib @RandyKoh24 @SeanM_Wu @Derek_Leong_RPh @VictorD…

Apr 10, 2020 · 1 share · 410 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio @rafavidalperez @DrRajivsankar @rbcasado @DrRaniKhatib @RandyKoh24 @SeanM_Wu @Derek_Leong_RPh @VictorDayan1 @OlivierHoffman @HeartOTXHeartMD @SuzanneArtMusic @ihtanboga @drwilsonjr optimal DAPT or optimal anticoagulation buddy ? everybody forgets that ATLAS TIMI-51 lowered total mortality by 1/3 in ACS in the group given aspirin & P2Y12 & baby dose rivaroxaban versus DAPT https://t.co/DYGAOgNv0U https://t.co/1WrRExlkQ1 @CMichaelGibson @DLBHATTMD

Apr 10, 2020 · 6 likes · 1 share · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@GreggWStone @SVRaoMD @fischman_david @TCTMD_Yael @TCTMD @rwyeh @CMichaelGibson @DocSavageTJU @rajivxgulati @ajaykirtane @Drroxmehran @mmamas1973 @mirvatalasnag Greg why do people forget about Atlas TIMI 51 where there was also a mortality benefit & reduction of stent thrombosis by adding baby dose rivaroxaban to P2Y12i and aspirin? https://t.co/DYGAOgNv0U after ISAR React 5 should we not repeat Atlas with Prasugrel and low dose NOAC?

Oct 19, 2019 · 3 likes · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@SABOURETCardio @DocSavageTJU @mmamas1973 @DrMarthaGulati @GreggWStone @Drroxmehran @rwyeh @SVRaoMD @DLBHATTMD @mirvatalasnag @sbrugaletta @HeartOTXHeartMD @willsuh76 @djc795 @sloaneguy @fischman_david @CMichaelGibson @DrSoniaAnand1 not in Atlas TIMI 51 "median time from index event to randomization was 4.7 days" https://t.co/DYGAOgNv0U this @CMichaelGibson paper argues for riva + SAPT https://t.co/oZ4Rwin5HD be interested in @DLBHATTMD view

Oct 4, 2019 · 6 likes · 3,933 followers View post →
Syed Shahrul Naz
@drshahrul80 · X

RT @DrDerekConnolly: @VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U a…

Aug 27, 2019 · 3 shares · 6,933 followers View post →
Doaa El Okda
@OkdaDr · X

RT @DrDerekConnolly: @VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U a…

Jul 23, 2019 · 3 shares · 1,240 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@VLSorrellImages @CardiacJoshi @ASE360 this of course might be IN PART why the Atlas TIMI 51 https://t.co/DYGAOgNv0U and COMPASS studies https://t.co/iPx4M1F9HE both showed impressive reductions in embolic stroke & death. I'd suggest we need a trial in LV thrombus of VKA versus triple therapy of DAPT+RIVA 2.5mg bid

Jul 23, 2019 · 7 likes · 3 shares · 3,933 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@mmamas1973 @pabeda1 @djc795 @SVRaoMD @EmileMehanna @cardioPCImom @Pooh_Velagapudi @nolanjimradial @Heartdoc530 @DrMauricioCohen @hect2701 @hectortamezmd @vass_vassiliou @evandrofilhobr @rwyeh @FahmiJFarah @Ravi_Hira_MD @aymanka @DrFerNunez @RodrigoBagur I agree and we often marinate these patients / treat medically in the first instance. Rivaroxaban already has a NICE recommendation https://t.co/1WrRExlkQ1 based on the Atlas TIMI 51 Trial https://t.co/DYGAOgNv0U Be interesting to do a trial !!

Jun 2, 2019 · 5 likes · 3,933 followers View post →